Eli Lilly & Co. reaffirmed its guidance for 2019 earnings, and expects revenues to continue to grow in the coming year.
The pharmaceutical company has projected 2020 non-GAAP earnings in the range of $6.70 to $6.80 per share, which exceeds the Refinitv forecast of $6.63 per share. The group also re-iterated its 2019 full-year earnings guidance (which it had boosted in October) at a range of $5.75 to $5.85 per share.
Eli Lilly is expecting revenues in the range of $23.6 billion to $24.1 billion, with a compound annual growth rate of 7%.
CEO David Ricks mentioned an expanding portfolio of new medicines focused on diabetes, oncology, immunology, and neuroscience as key drivers of growth for the company.
Ricks also cited “attractive commercial portfolio and limited patent exposure through the latter half of the upcoming decade” as factors that should enable the company to deliver sustainable volume-based revenue growth and drive further operating margin expansion.
LLY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 31 cases where LLY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 358 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on October 22, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on October 23, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
LLY moved below its 50-day moving average on October 17, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on October 07, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LLY entered a downward trend on October 09, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (67.114) is very high in comparison to the industry average of (5.632). P/E Ratio (131.129) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (1.440) is also within normal values, averaging (3.004). Dividend Yield (0.006) settles around the average of (0.164) among similar stocks. LLY's P/S Ratio (20.121) is very high in comparison to the industry average of (3.643).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor